|
市場調査レポート
HIV：診断および治療市場
HIV: Markets for Diagnostics and Therapeutics
|
Abstract
The strategic concept of HIV/AIDS diagnosis and therapy is one of the most
complex that the healthcare industry has ever seen. In order to cope with the
challenges and opportunities of HIV/AIDS diagnostics and therapeutics,
companies must think on a global basis. In addition to the basic pathology and
complications of HIV/AIDS, there are primarily three focal points for the
development of strategy in this area: potential market, epidemiology (HIV/AIDS
patient trends) and technology.
In his report HIV Markets for Diagnostics and Therapeutics, anlayst Kenneth
Krul, PhD examines these focal points, with an eye to creating a comprehensive
look at the market and opportunity for both testing and treatments of HIV. Dr.
Krul takes a look at the potential theoretical markets and what will be
realistic in the current world healthcare system.
The report contains extensive epidemological statistics for HIV in the following WHO health regiions:
- Sub-Saharan Africa
- Middle East and North Africa
- South and South-East Asia
- East Asia
- Latin America
- Caribbean
- Eastern Europe and Central Asia
- Western and Central Europe
- North America
- Oceania
In addition the report contains:
- Current Market Sizes for HIV Treatments and Diagnostics in each WHO Health
Region (treatment and diagnostic markets)
- Profiles of Companies in this Market
- Eleven Important Conclusions
- Review of Current Treatment Products and Diagnostic Tools.
As with all Kalorama Information reports, this product is the result of
primary and secondary research. Interviews with experts, as well as research
into company reports, medical literature and government data is included.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Potential and Realistic Markets
- Figure 1-1: “Theoretical” Distribution of HIV Market
- Figure 1-2 Realistic Market for HIV/AIDs Diagnostics
- Table 1-1: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008
- Table 1-3: Regional HIV/AIDS Statistics: 2001 and 2007
- Technology
- Key HIV/AIDS Market Issues
- Scope and Methodology
CHAPTER TWO: INTRODUCTION AND EPIDEMIOLOGY
- HIV/AIDS Complications
- HIV/AIDS Epidemiology
- Table 2-1: Global Summary of HIV/AIDS Populations: 2007 (Category,
Average, Range)
- Figure 2-1: Estimated People Living With HIV/AIDS Globally: 1990 - 2007
- Figure 2-2: Estimated Number of Adult and Child Deaths Due to AIDS
Globally: 1990 - 2007
- Figure 2-3: Estimated Incidence of HIV Infection Globally: 1990 - 2007
Sub-Saharan Africa
- Table 2-2: Regional HIV/AIDS Statistics (I): 2001 and 2007 (Millions)
- Table 2-3: Regional HIV/AIDS Statistics (II): 2001 and 2007
- Figure 2-4: Estimated HIV Prevalence Rates (%) in Adults (15 - 49 Years)
Globally and in Sub-Saharan Africa: 1990 - 2007
- Table 2-4: Adult (Aged 14 - 49 years) HIV Prevalence in Sub-Saharan
Countries That Have Recently Conducted Population-Based HIC Studies
- Table 2-4 (continued): Adult (Aged 14 - 49 years) HIV Prevalence in Sub-
Saharan Countries That Have Recently Conducted Population-Based HIC Studies
- Asia
- Eastern Europe and Central Asia
- The Caribbean
- Latin America
- North America, Western and Central Europe
- Figure 2-5: AIDS Distribution by Race in the United States: 2006
- Figure 2-6: Risk Factors Associated with AIDS in Men in the United States:
2006
- Table 2-5: Prevalence of HIV Infection in the United States Based on
Sample Testing: 2006
- Figure 2-5: AIDS Distribution by Race in the United States: 2006
- Figure 2-6: Risk Factors Associated with AIDS in Men in the United States:
2006
- Figure 2-7: Risk Factors Associated with AIDS in Women in the United
States: 2006
- The Middle East and North Africa
CHAPTER THREE: HIV/AIDS SCREENING AND DIAGNOSIS
- Level 1: Screening
- Level 2: Confirmatory Testing
- Level 3: Diagnosis
- Table 3-1: HIV Screening and Confirmatory Testing Products Approved for
Use in the United States as of July 9, 2008
- Table 3-2: Conditions Attributable to or Complicated by HIV
- Table 3-3: AIDS Indicator Conditions
- Level 4: Monitoring Treatment and Prognosis
CHAPTER FOUR: HIV/AIDS THERAPEUTICS
- Drug Therapy
- Figure 4-1: Binding of HIV to T-Cells
- Table 4-1: HIV Entry/Fusion Inhibitors; FDA-Approved and in Development:
2008
- Table 4-2: Nucleoside Reverse Transcription Inhibitors (NRTI);
FDA-Approved and in Development: 2008
- Table 4-3: Non-Nucleoside Reverse Transcription Inhibitors (NNRTI);
FDA-Approved and in Development: 2008
- Figure 4-3: HIV Integration
- Table 4-4: Integrase Inhibitors; FDA-Approved and in Development: 2008
- Figure 4-4: HIV Transcription
- Figure 4-5: HIV Translation
- Figure 4-6: HIV Assembly and Maturation
- Table 4-5: Protease Inhibitors (PI)/Maturation Inhibitors (MI);
FDA-Approved and in Development: 2008
- Pediatric HIV/AIDS
- Table 4-6: Anti-HIV Drugs in Development: 2008
- Table 4-7: Anti-HIV Drugs Approved for Pediatric Use
- Chemokine Therapeutics and HIV
- Genes and HIV/AIDS
- HIV/AIDS Vaccines
CHAPTER FIVE: MARKET ANALYSIS
- Table 5-1: Estimated Theoretical Potential for HIV/AIDS Diagnostics and
Therapeutics: 2008
- Figure 5-1 HIV/AIDS Market by Major World Regions
- Table 5-2: Global Market for HIV/AIDS Diagnostics and Therapeutics: 2008
Technology Key HIV/AIDS Market Issues
CHAPTER SIX: COMPANY SNAPSHOTS
- Abbott Laboratories
- Abbott Molecular Diagnostics
- Bristol-Myers Squibb
- Calypte Biomedical Corp.
- Celera Diagnostics
- Gen-Probe Incorporated
- Gilead Sciences
- GlaxoSmithKline plc
- Luminex Corporation
- QIAGEN GmbH
- Roche Molecular Systems
- Tibotec, Inc. (A Johnson & Johnson Company)
- VIRxSYS Corporation
CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
- Seventh Conclusion
- Eighth Conclusion
- Ninth Conclusion
- Tenth Conclusion
- Eleventh Conclusion
CHAPTER EIGHT: GLOSSARY
|
